(Amherst, NH) – The transition of injectable drug packaging from vials to sophisticated and customized injection devices is accelerating at a time when caregiver and patient expectations continue to evolve. The result is an emerging set of de facto requirements for drug developers that often dictates the device strategy for a particular parental drug. This trend is strongly aligned within and...
(Amherst, NH) – The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has been driven by changes at the technology, regulatory, and therapeutic levels, and resulted in an ongoing set of challenges and opportunities for market participants that has modified the dynamics of injectable...
(Amherst, NH) – The convergence of biological drug development and applied genetics is moving beyond traditional models of therapeutic drug administration and creating challenges for medical technologists. By targeting biologicals at the cellular level, researchers are attempting to establish a new generation of therapeutics that has the potential to approach the precision and accuracy envisioned...
(Amherst NH) – Growth of transdermal delivery has been restricted by the need to limit candidate drugs to molecules small enough to passively migrate through the stratum corneum, a limitation that excludes passive transdermal patches as a viable option for the growing number of therapeutic compounds that will represent an increasing share of future NCEs. To expand the limits of transdermal...
(Amherst, NH) – As drug developers endeavor to differentiate their products in the age of direct-to-consumer marketing, delivery technologies, once viewed as specialty or niche routes of administration are gaining more attention, particularly with regard to their perceived value in addressing the needs of specific patient populations. Because it relies on passive diffusion to effect drug...
(Amherst, NH) – While many investors and market observers gave up on alternative insulin delivery after the collapse of the inhaled insulin market in 2008, more than a dozen innovative and focused companies have not. A significant number of programs focused on alternative insulin delivery technologies continue to move forward. In terms of the range of formulation strategies and delivery...
(Amherst, NH) – As the pharmaceutical industry attempts to improve productivity and lower the business risks associated with new drug candidates, drug developers are increasingly turning to a generation of new, often proprietary, formulation and delivery technologies. These technologies can modulate release profiles to achieve dosage forms that enhance patient outcomes, compliance and safety...
(Amherst, NH) – The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the...
(Amherst, NH) – With tens of millions of surgical procedures performed annually, the market for wound closure products and techniques is significant. In the U.S. alone, more than one hundred thousand surgeries are being performed daily. This market is expected to grow further as an aging world population creates increased demand for all types of surgical intervention, particularly cardiovascular...
(Amherst, NH) – Transdermal drug developers are being challenged by a market that is growing in range as well as depth. The availability of APIs in patch and gel form for indications beyond hormone replacement are creating opportunities to penetrate therapeutic segments that represent sustainable growth models. Over the coming decade, growth in demand for prescription drug patches will be driven...